Study Shows Merck’s Gardasil Leads to Major Decline of HPV
Tuesday, June 21, 2016
A new analysis, citing a decade’s worth of real-world data for Merck’s Gardasil, which is manufactured in Merck’s Elkton plant, shows a nearly 90% decrease in HPV incidence in countries with the highest vaccination rates against HPV. This study, led by the Royal Women’s Hospital at the University of Melbourne, Australia, looked at 58 studies in 9 countries over a nine-year span.
In areas with the best coverage, the analysis also found reductions of approximately 90% for genital warts, 90% for high-grade histologically proven cervical abnormalities and 60% for low-grade cytological cervical abnormalities. The data was gathered from PubMed and Embase, with the impact of Gardasil becoming “increasingly evident” over the course of the period. More than 205 million Gardasil doses had been distributed as of Dec. 31, 2015, the team noted.
In February 2016, all 69 of the National Cancer Institute's Cancer Centers joined together to issue a statement calling for higher use of the vaccine. In the past 10 years the HPV vaccination rates in teenage girls fell by nearly two-thirds. They contribute this to antivaccine campaigns, safety concerns, a sex stigma and pediatricians' reluctance to discuss the jabs
According to the CDC’s numbers for 2015, just 40% of girls and 21% of boys in the U.S. have received the vaccines. An Health and Human Services 2020 initiative has set HPV vaccination goals for both boys and girls at 80%.